Rafferty Asset Management
CLVS

Rafferty Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Rafferty Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,333,278
Closed -$3.61M – 1350
2021
Q4 		$3.61M Buy
1,333,278
+618,590
+87% +$2.29M 0.02% 494
2021
Q3 		$3.19M Buy
714,688
+263,392
+58% +$1.27M 0.02% 443
2021
Q2 		$2.62M Sell
451,296
-109,628
-20% -$642K 0.02% 569
2021
Q1 		$3.94M Buy
560,924
+368,716
+192% +$2.47M 0.03% 348
2020
Q4 		$923K Sell
192,208
-136,295
-41% -$689K 0.01% 526
2020
Q3 		$1.92M Buy
328,503
+187,227
+133% +$1.12M 0.02% 427
2020
Q2 		$954K Buy
141,276
+124,431
+739% +$942K 0.01% 561
2020
Q1 		$107K Sell
16,845
-126,265
-88% -$1.01M ﹤0.01% 555
2019
Q4 		$1.49M Buy
+143,110
New +$1.04M 0.02% 456
2019
Q3 		– Sell
-367,079
Closed -$5.46M – 866
2019
Q2 		$5.46M Buy
367,079
+186,542
+103% +$3.37M 0.1% 143
2019
Q1 		$4.48M Buy
+180,537
New +$4.53M 0.07% 156

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Rafferty Asset Management's CLVS Position: Q1 2022 in Review

Rafferty Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 1,333,278 shares — an estimated $3.61M sold.

Rafferty Asset Management first reported a position in CLVS in Q1 2019 and held it in 11 quarters. The position peaked at $5.46M in Q2 2019. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Rafferty Asset Management reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 1,333,278 Clovis Oncology, Inc. shares in Q1 2022, an estimated $3.61M.
  • Rafferty Asset Management first reported a position in Clovis Oncology, Inc. in Q1 2019 and held it in 11 quarters.
  • Rafferty Asset Management's Clovis Oncology, Inc. position peaked at $5.46M in Q2 2019.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.